Immunotherapy's Great Potential for Ovarian Cancer
Why are the results so slow?
In regards to the role of immunotherapy in the treatment of ovarian cancer, there are currently studies underway to test the structure of checkpoint inhibitors and their impact. At the moment, the studies are in their early stages and the data gathered is limited.
“One of the reasons that the results are slow coming forward is because we do need to follow these patients for a period of time. No longer can you use surrogate markers such as tumor response to give us an indication that these drugs are active—actually, the response rates are not that high. Therefore, we have to look at the length of disease control, progression free-survival and perhaps even overall survival to get a feeling of whether these agents will be helpful for these patients. That is why we don't have those data yet,” said Professor Ledermann.
